Impact of Octreotide on Early Complications After Liver Transplant: A Randomized, Double-Blind Placebo-Controlled Trial

被引:1
|
作者
Lankarani, Kamran Bagheri [1 ]
Safa, Hoda [2 ,4 ]
Ghahramani, Sulmaz [1 ]
Sayari, Mohammad [1 ]
Malekhosseini, Seyed-Ali [3 ]
机构
[1] Shiraz Univ Med Sci, Inst Hlth, Hlth Policy Res Ctr, Shiraz, Iran
[2] Shiraz Univ Med Sci, Dept Gastroenterol, Shiraz, Iran
[3] Shiraz Univ Sci, Shiraz Transplant Res Ctr, Shiraz, Iran
[4] Hormozgan Univ Med Sci, Dept Gastroenterol, Bandar Abbas, Iran
关键词
Acute kidney injury; Early allograft dysfunction; Length of hospital stay; Nosocomial infection; Somatostatin analog; EARLY ALLOGRAFT DYSFUNCTION; ISCHEMIA-REPERFUSION INJURY; RENAL-FUNCTION; HYPERTENSION; DEFINITION; VALIDATION; BAICALIN;
D O I
10.6002/ect.2022.0080
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Objectives: Acute kidney injury and early allograft dysfunction are 2 common complications after liver transplant. Octreotide, through its various mechanisms, may have a role in preventing these complications.Materials and Methods: In this randomized, double-blind placebo-controlled clinical trial, we randomly assigned 50 patients who underwent deceased donor liver transplant and fulfilled the study inclusion requirements to receive either octreotide infusion for 3 days in the first 3 days after transplant in the intensive care unit or placebo. The eligible patients were properly informed while on the transplant wait list and gave their consent to participate in the study. The rates of acute kidney injury within the first 7 days after transplant (based on KDIGO criteria), early allograft dysfunction, and nosocomial infection; total length of hospital stays and intensive care unit admissions; and intubation time were recorded and compared between the 2 groups.Results: No significant differences were found between the 2 groups with regard to demographic charac-teristics and graft factors (P > .05). However, acute kidney injury, early allograft dysfunction, and nosocomial infection rates were significantly lower in the octreotide group compared with the control group (P < .05). Moreover, a significant difference was observed between the 2 groups with regard to length of hospital stay and intensive care unit admissions (P < .05). For infection, female patients had a higher likelihood of infection than male patients (odds ratio = 23.19). Intensive care unit admission was associated with a higher probability of early graft dysfunction (odds ratio = 1.34). In contrast, longer intubation time was associated with a decrease in the probability of early graft dysfunction (odds ratio = 0.93).Conclusions: This study showed that octreotide infusion in the first 3 days after liver transplant could improve renal and allograft function and reduce infection and length of hospital stay.
引用
收藏
页码:835 / 841
页数:7
相关论文
共 50 条
  • [1] RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF EARLY OCTREOTIDE IN PATIENTS WITH POSTOPERATIVE ENTEROCUTANEOUS FISTULA
    SANCHO, JJ
    DICOSTANZO, J
    NUBIOLA, P
    LARRAD, A
    BEGUIRISTAIN, A
    ROQUETA, F
    FRANCH, G
    OLIVA, A
    GUBERN, JM
    SITGESSERRA, A
    BRITISH JOURNAL OF SURGERY, 1995, 82 (05) : 638 - 641
  • [2] RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF EARLY OCTREOTIDE IN PATIENTS WITH POSTOPERATIVE ENTEROCUTANEOUS FISTULA
    JENKINS, SA
    JAVLE, P
    PARSONS, KF
    BALAN, KK
    BEREIN, A
    BRITISH JOURNAL OF SURGERY, 1995, 82 (11) : 1576 - 1576
  • [3] Prophylactic fluconazole in liver transplant recipients - A randomized, double-blind, placebo-controlled trial
    Winston, DJ
    Pakrasi, A
    Busuttil, RW
    ANNALS OF INTERNAL MEDICINE, 1999, 131 (10) : 729 - +
  • [4] Double-Blind, Placebo-Controlled, Randomized Trial of Octreotide in Malignant Bowel Obstruction
    Currow, David C.
    Quinn, Stephen
    Agar, Meera
    Fazekas, Belinda
    Hardy, Janet
    McCaffrey, Nikki
    Eckermann, Simon
    Abernethy, Amy P.
    Clark, Katherine
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2015, 49 (05) : 814 - 821
  • [5] Double-blind randomized placebo-controlled trial of sibutramine
    Bray, GA
    Ryan, DH
    Gordon, D
    Heidingsfelder, S
    Cerise, F
    Wilson, K
    OBESITY RESEARCH, 1996, 4 (03): : 263 - 270
  • [6] Applicability of Press Needles to a Double-blind Trial A Randomized, Double-blind, Placebo-controlled Trial
    Miyazaki, Shougo
    Hagihara, Akihito
    Kanda, Ryo
    Mukaino, Yoshito
    Nobutomo, Koichi
    CLINICAL JOURNAL OF PAIN, 2009, 25 (05): : 438 - 444
  • [7] Octreotide in hepatorenal syndrome: A randomized, double-blind, placebo-controlled, crossover study
    Pomier-Layrargues, G
    Paquin, SC
    Hassoun, Z
    Lafortune, M
    Tran, A
    HEPATOLOGY, 2003, 38 (01) : 238 - 243
  • [8] Marfan Sartan: a randomized, double-blind, placebo-controlled trial
    Milleron, Olivier
    Arnoult, Florence
    Ropers, Jacques
    Aegerter, Philippe
    Detaint, Delphine
    Delorme, Gabriel
    Attias, David
    Tubach, Florence
    Dupuis-Girod, Sophie
    Plauchu, Henry
    Barthelet, Martine
    Sassolas, Francois
    Pangaud, Nicolas
    Naudion, Sophie
    Thomas-Chabaneix, Julie
    Dulac, Yves
    Edouard, Thomas
    Wolf, Jean-Eric
    Faivre, Laurence
    Odent, Sylvie
    Basquin, Adeline
    Habib, Gilbert
    Collignon, Patrick
    Boileau, Catherine
    Jondeau, Guillaume
    EUROPEAN HEART JOURNAL, 2015, 36 (32) : 2160 - U37
  • [9] A double-blind, randomized, placebo-controlled laser trial methodology
    Oussedik, E.
    Saleem, M. D.
    Patel, N. U.
    Feldman, S. R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : B11 - B11
  • [10] A randomized, double-blind, placebo-controlled trial of pseudoephedrine in coryza
    Latte, J
    Taverner, D
    Slobodian, P
    Shakib, S
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2004, 31 (07): : 429 - 432